Nuzenio

Ras Adc Phase

Ras Adc Phase news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 7 latest news signals 7 publisher sources 100/100 entity strength

Latest news

IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update - MorningstarMorningstar · Tue, 04 Aug 2026 15:00:00 GMTAdlai Nortye Wins HREC Approval for AN4035 Pan-RAS ADC Phase I Trial - The Clinical Trial VanguardThe Clinical Trial Vanguard · Tue, 04 Aug 2026 07:38:27 GMTAdlai Nortye (NASDAQ: ANL) secures ethics nod for AN4035 Phase I cancer trial - Stock TitanStock Titan · Mon, 03 Aug 2026 12:00:53 GMTAdlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia - The Manila TimesThe Manila Times · Mon, 03 Aug 2026 11:19:31 GMTAdlai Nortye Announces First-in-Class AN4035 Cleared for Phase I Clinical Development as First Pan-RAS(ON) ADC to Enter the Clinic - Quiver QuantitativeQuiver Quantitative · Mon, 03 Aug 2026 11:15:00 GMTAdlai Nortye starts Phase I trial for first-in-class pan-RAS(ON) inhibitor ADC AN4035 in Australia - PluangPluang · Mon, 03 Aug 2026 07:00:00 GMTBiotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure? - TradingViewTradingView · Mon, 03 Aug 2026 02:48:00 GMT

Timeline

Tue, 04 Aug 2026 15:00:00 GMTIDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update - Morningstar
Tue, 04 Aug 2026 07:38:27 GMTAdlai Nortye Wins HREC Approval for AN4035 Pan-RAS ADC Phase I Trial - The Clinical Trial Vanguard
Mon, 03 Aug 2026 12:00:53 GMTAdlai Nortye (NASDAQ: ANL) secures ethics nod for AN4035 Phase I cancer trial - Stock Titan
Mon, 03 Aug 2026 11:19:31 GMTAdlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia - The Manila Times
Mon, 03 Aug 2026 11:15:00 GMTAdlai Nortye Announces First-in-Class AN4035 Cleared for Phase I Clinical Development as First Pan-RAS(ON) ADC to Enter the Clinic - Quiver Quantitative
Mon, 03 Aug 2026 07:00:00 GMTAdlai Nortye starts Phase I trial for first-in-class pan-RAS(ON) inhibitor ADC AN4035 in Australia - Pluang

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Ras Adc Phase.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

7 distinct publisher/source names are currently connected to this entity page.